AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer's disease progressionAC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billionAC Immune to h ...

, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...

ANNUAL REPORT 2023 Contents | AC Immune Annual Report 2023 1 Contents 2 Operating and Financial Highlights Our goal is global leadership 3 Chair & CEO’s Statement ...

A downtrend has been apparent in AC Immune (ACIU) lately with too much selling pressure. The stock has declined 35.7% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spott ...

AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company's strategy is focused on advancing the Phase 2 development of its three active immunotherapiesActive immunotherapy now considered to be the optimal approach for precision prevention of neurodegenerative diseases Lausanne, Switzerland, January 22, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company will regain all glob ...

Wall Street had a disappointing start to 2024 as the nine-week winning streak snapped, erasing some of the strong gains seen at the end of 2023. Overstretched valuations and uncertainty around when the Fed will begin to cut rates have dampened investors’ optimism. The decline was broad-based, with small-cap stocks plunging the most.The Russell 2000 Index declined 3.7% in the initial week of 2024. The trend might reverse, given what is called the “January Effect," which refers to a seasonal increase in stock ...

Investors might want to bet on AC Immune (ACIU) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since ...

AC Immune SA项目更新 - AC Immune SA提供了关于其活性免疫疗法项目的进展更新[3] ACI-24.060的ABATE Phase 1b/2 AD试验 - ACI-24.060的ABATE Phase 1b/2 AD试验已完成1和2组的招募，并预计将于2024年1月完成第3组的招募[1] ACI-35.030的ReTain Phase 2b临床试验 - ACI-35.030的ReTain Phase 2b临床试验正在进行中，由合作伙伴启动[2]

资产情况 - 非流动资产总额为56,807千瑞士法郎，较上一期57,844千瑞士法郎略有下降[1] - AC Immune 在2023年9月30日的现金及现金等价物为31,927千瑞士法郎[28] - AC Immune 在2023年9月30日的短期金融资产为48,000千瑞士法郎[28] - AC Immune 在2023年9月30日的无形资产中，收购的IPR&D资产为50,416千瑞士法郎，未进行摊销[26] - AC Immune 在2023年9月30日的财产、厂房和设备净账面价值为3,627千瑞士法郎[21] - AC Immune 在2023年9月30日的租赁资产净账面价值为2,403千瑞士法郎[22] 财务表现 - 当期营业收入为3,934千瑞士法郎，较去年同期3,934千瑞士法郎持平[2] - 净现金流量用于经营活动为-44,217千瑞士法郎，较上一期-56,161千瑞士法郎有所改善[4] - AC Immune 在2023年前九个月短期金融资产到期投资净收益为43.0百万瑞士法郎，较之前同期的20.0百万瑞士法郎有所增长[28] - AC Immune 在2023年9月30日的预付费用包括预付的研发和行政成本，总额为5.5百万瑞士法郎[27] - AC Immune 在2023年9月30日的员工定义福利负债为0.6百万瑞士法郎[24] - AC Immune 在2023年9月30日的应计费用包括研发成本、工资费用和其他应计费用，总额为9.3百万瑞士法郎[25] - AC Immune 在2023年9月30日的授权收入为0瑞士法郎，较之前同期的3.9百万瑞士法郎有所下降[16] 股份交易 - 公司在2023年第二季度出售了712,993股以前持有的库藏股，募集了2.3百万美元净额[29] - 公司在2023年第三季度出售了205,015股以前持有的库藏股，募集了0.6百万美元净额[29] - 截至2023年9月30日和2022年12月31日，公司分别持有5,296,013股和6,214,021股库藏股[29]

资产状况 - 非流动资产总额为57,076千瑞士法郎，较上一期减少了768千瑞士法郎[1] - 股东权益总额为139,328千瑞士法郎，较上一期减少了29,663千瑞士法郎[3] 盈利情况 - 当期亏损为16,833千瑞士法郎，较去年同期减少了2,810千瑞士法郎[2] 偿债能力 - 公司认为自己能够在至少12个月内按时履行所有义务，考虑到截至2023年6月30日的公司现金状况为4千万瑞士法郎和短期金融资产为5千3百万瑞士法郎[13] 收入情况 - 截至2023年6月30日，公司未生成任何合同收入[16] 资助情况 - 公司从迈克尔·J·福克斯基金会获得了总额为0.5百万美元（0.5百万瑞士法郎）的续约资助，用于继续开发其α-突触核蛋白PET成像诊断试剂[18]